The economic cost of IPR infringement in the pharmaceutical sector

News

Printer-friendly versionPDF version

The European Union Intellectual Property Office (EUIPO) has published a report on the IPR infringement in the pharmaceutical industry.

This report shows that the legitimate industry loses approximately EUR 10 billion of revenue annually due to the presence of counterfeit medicines in the EU marketplace, corresponding to 4.4% of the sector’s sales.

Those lost sales translate into 37,700 jobs directly lost across the pharmaceutical sector in the EU, as legitimate manufacturers and distributors of pharmaceuticals employ fewer people than they would have done in the absence of counterfeiting.

The full report is available here.